The shadow of generic challenges has repeatedly loomed over copyright’s blockbuster drug, Viagra, raising questions about the outlook of related drug portfolios. While initial times saw impressive returns, the intellectual property end has opened the way for discounted substitutes, possibly reducing profitability and posing a real hazard for inve